The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine  by Moradi, Mandana et al.
Respiratory Medicine (2009) 103, 434e441ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedThe role of glutathione-S-transferase
polymorphisms on clinical outcome of ALI/ARDS
patient treated with N-acetylcysteineMandana Moradi a, Mojtaba Mojtahedzadeh a, Ali Mandegari b,c,
Mohammad Sadegh Soltan-Sharifi b, Atabak Najafi d,
Mohammad Reza Khajavi d, Molook Hajibabayee a,
Mohammad Hossein Ghahremani b,e,*a Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
b Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences,
Tehran, Iran
c Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kerman University of Medical Sciences,
Kerman, Iran
d School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
e Department of Molecular Medicine, School of Advanced Technology in Medicine, Tehran University of
Medical Sciences, Tehran, Iran
Received 23 March 2008; accepted 22 September 2008






Genetic variation* Corresponding author. Department
Medical Sciences, 14155 Tehran, Iran.
E-mail address: mhghahremani@tu
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.09.013Summary
Oxidative stress has a proven role in pathophysiology of acute respiratory distress syndrome.
The antioxidant drugs, especially N-acetylcysteine (NAC) have been used for years to over-
come oxidative stress effects in patients. In the present study we have investigated the effects
of NAC treatment (IV NAC in 150 mg/kg at the first day followed by 50 mg/kg/day for three
days) on 27 ICU patients with ALI/ARDS considering the glutathione-S-transferase genetic vari-
ations, as an important enzyme contributing in oxidative stress pathways. The results indi-
cated that NAC improved oxygenation (increase in PaO2/FiO2) and decreased mortality rate
in treated patients compared to control group (p< 0.05). Evaluation of three isoforms of gluta-
thione-S-transferase (GST M1, P1 and T1), in these patients have showed an association
between GST M1 null, and GST M1 and T1 double null polymorphisms with increased mortality
in control group, suggesting antioxidant therapy critical for this group of patients.
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Acute respiratory distress syndrome (ARDS)/acute lung
injury (ALI) is a serious clinical problem, which is
a contributor to the morbidity and mortality of patients in
intensive care units all over the world, impairing tremen-
dous human and financial costs. Despite advances in
supportive care, the mortality rate in patients with the ALI/
ARDS is still high and varies from 10% to as high as 90%1
resulting in approximately 80,000 deaths yearly in the
United States.2 Since the original description of ARDS/ALI,
investigators have endeavored to elucidate the mechanisms
regulating the pathways leading to lung injury in ALI/ARDS,
with the ultimate goal of developing therapeutic tools to
ameliorate or prevent lung injury in patients at risk. One
important fact in the pathogenesis of ALI/ARDS, and one
that is the focus of our study, is oxidative injury to the lung
mediated by Reactive Oxygen Species (ROS).3e5 This leads
to cell injury by various mechanisms including direct DNA
damage, lipid peroxidation, oxidation of proteins,6e8
releasing of proteases and inactivation of antioxidant and
antiprotease enzymes,9 and alteration of transcription
factors such as activator protein-1 and nuclear factor (NF)-
kB, leading to enhanced expression of proinflammatory
genes.10,11
Glutathione system (GSH/GSSG) is an important and the
most abundant antioxidant in the lung that decreases in
lung inflammatory conditions such as ARDS/ALI.12 Thus
one strategy to limit oxidative lung injury is to restore
the oxidant/antioxidant balance by augmenting the
intracellular pool of glutathione using its precursors,
such as N-acetylcysteine (NAC).13e15 NAC can stimulate
GSH synthesis, enhance glutathione-S-transferase (GST)
activity, promote detoxification, and act directly on reac-
tive oxidant radicals. Moreover, NAC reduces the formation
of proinflammatory cytokines, such as interleukin-8 and
tumor necrosis factor-[alpha].16 Protective effects of NAC
have been described in many experimental and clinical
models of ARDS. In mechanically ventilated patients with
acute lung injury, NAC has increased cellular glutathione
content, decreased the blood levels of conjugated dienes,
variables of oxidative stress,17 improved systemic oxygen-
ation and reduced ventilatory requirements,18 improved
chest radiograph edema and vascular resistance resulting
better survival rate.
Reports on administration of NAC in ARDS are still con-
flicting and some trials have not demonstrated its effi-
cacy.19 Therefore, we hypothesized that genetic
differences in study populations, especially in genes
involved in oxidative stress, may have contributed to these
diverse results. Glutathione-S-transferases (GSTs) have
considerable impact upon oxidative stress in critically ill
patients. GSTs are a complex multigene family of enzymes
that are widely distributed in the animal kingdom and
catalyze the conjugation of glutathione to a wide range of
compounds and possess many biological functions, such as
detoxification of xenobiotics, removal of reactive oxygen
species and regeneration of S-thiol proteins.20 These
enzymes have important role in oxidative stress pathways,
and data support the view that allelism in different GST
genes mediates susceptibility and outcome in differentdiseases,21e26 especially in the cases mediated by oxidative
stress. The major GST enzyme in the human lung is GST P1,
with the common polymorphism leading to replacement of
the amino acid Val with Ile at codon 105. This substitution
results in three possible genotypes: 105 Ile/Ile, 105 Ile/Val,
or 105 Val/Val, and also changes the enzyme active site and
it’s substrate-specific catalytic activity.21,23 These poly-
morphisms have been studied widely as a potential
contributor in asthma, COPD and lung cancers, but related
available data are still conflicting.25e27 Since GST M1, GST
P1, and GSTT1 are the most commonly examined genes in
GST family, with documented role in oxidative stress
pathways,25e28 in this study we have investigated the role
of polymorphisms of these three classes of enzyme in
clinical response of ARDS patients treated with NAC.
Subjects and methods
Recruitment of subjects
Following ethics committee approval (by the Institutional
Review Board of Medical Ethics, Pharmaceutical Sciences
Research Center/Tehran University of Medical Sciences), 30
consecutive mechanically ventilated patients meeting
criteria for ALI/ARDS, were recruited between July 2005 and
April 2006 from the General ICU of Sina hospital, one of the
principal teaching hospitals of Tehran University of Medical
Sciences. ALI/ARDS was defined according to the criteria
established by the AmericaneEuropean Consensus Confer-
ence on ARDS29 (acute onset, PaO2/FiO2< 300 mmHg, bilat-
eral infiltrates seen on frontal chest radiograph, and
pulmonary artery occlusion pressure below 18 mmHg). The
patients must also have SIRS concomitantly (Systemic
Inflammatory Response Syndrome: 2 or more of the following
conditions, temperature> 38 C or <36 C, heart rate> 90 -
beats/min, respiratory rate> 20/minor PaCO2< 32 mmHg,
WBC> 12,000 or <4000 cells/mm3 or 10% bands).
The patients with PaO2/FiO2> 300, age< 18 years,
hepatic or renal failure not due to septic shock and preg-
nancy were excluded. The design was a prospective
randomized single blinded, placebo controlled clinical trial.
Clinical protocol
Following randomization (simple randomization) patients
received either NAC, or the equal volume of placebo (5%
dextrose) as soon as the clinical diagnoses of ALI/ARDS
were established (within few hours of admission). The dose
of NAC in this study was 150 mg/kg diluted in 5% dextrose
that was infused in a period of 20 min at first day and then
50 mg/kg/day diluted in 5% dextrose for 3 additional doses
in 3 consecutive days. All patients received routine
supportive therapy for ALI/ARDS including mechanical
ventilation, fluid managements and treatments for their
underlying pathology. None of these patients received any
investigational drug or surfactant.
At the beginning of the study and initiating NAC, the past
medical history and physical, laboratory and homodynamic
variables as well as ventilatory support measures were
recorded and the presence of comorbid conditions (see the
436 M. Moradi et al.subsequent discussion) was noted. The APACHE II score was
calculated within 6 h of initiation of NAC.30 Physiologic and
laboratory characteristics prior to initiation of NAC were
measured to determine the development of non-pulmonary
organ-system dysfunction (ODS) between the time of ICU
admission and initiation of our intervention or after that.
The characteristics of the patient’s population are
summarized in Table 1. In all patients we recorded daily
oxygenation indices (PaO2, FiO2 and PaO2/FiO2) during the
course of NAC administration, length of intubations, and
hospital mortality as our clinical end points.
Definitions
On the basis of previously published data, comorbid
conditions most likely to affect mortality are as follows.31
Malignancy (active, untreated or undergoing current
treatment), cirrhosis (biopsy proven or with evidence of
portal hypertension), HIV infection (serologic evidence of
infection with or without AIDS), organ transplantation
(history of bone morrow, liver or kidney transplantation),
chronic obstructive pulmonary disease (COPD), alcohol
abuse, intravenous drug use (IVDU), chronic steroid use
(current use of corticosteroid for >2 weeks and dos-
e> 20 mg/day), and diabetes mellitus.
Non-pulmonary organ dysfunction was defined as such
a dysfunction developing after admission to the hospital
and persisting through the time of initiation of mechanical
ventilation or during mechanical ventilation in a specific
organ system, as follows.
Hepatic dysfunction (total serum bilirubin> 2.0 mg/dl,
along with a prothrombin time> 3 s longer than the control
value), renal dysfunction (serum creatinine> 2 mg/dl),
hematologic dysfunction (platelet count of <75,000/mm3,
WBC< 1000/mm3 or evidence of disseminated intravascular
coagulation (DIC)), neurological dysfunction (obtundation,
seizure, hemorrhage or acute cerebrovascular accident),
and gastrointestinal dysfunction (ileus lasting> 24 h or
hemorrhage requiring transfusion).
Blood sampling
Blood samples were taken (approximately 7 ml) from
indwelling arterial cannula in a tube containing 0.1 mmol/l






Age (years) 48.4 5.5 49.2 4.5 0.912
Gender (M/F) 9/5 8/5 0.598
APACHE II 18.3 1.0 21.1 2.0 0.198
PaO2/FiO2 (mmHg) 194.5 40.5 139.1 15.3 0.225
Organ dysfunction 14 13 0.756
Systemic comorbidities 6 6 0.863
Data are presented as median SE. For statistical analysis
Fisher’s Exact Test (for gender), t-test (for age, PaO2/FiO2),
Chi-square tests (for systemic comorbidity) and ManneWhitney
test (for organ dysfunction) were used.blood samples were centrifuged (3000 rpm, and 10 min) to
separate buffy coat layer, containing white blood cells.
Then stored at 80 C for DNA isolation and genotype
analyses.
Genotype analysis
DNA was isolated using salting out method. The DNA yield
was estimated by measuring the optical density at 260 nm
in a spectrophotometer prior to PCR reaction. A multiplex
PCR was performed to detect the presence or absence of
the GST M1 and GST T1 genes, according to the protocol
described previously by Abdel-Rahman et al.32 This tech-
nique conclusively identified GST M1 null and GST T1 null
genotypes, corresponding to the deletion of both alleles
and b-globin as an internal positive control. Primers used to
amplify the GST M1 genotypes were 50-GAA CTC CCT GAA
AAG CTA AAG C-30 and 50-GTT GGG CTC AAA TAT ACG GTG
G-30 as forward and reverse primers, respectively, resulting
in a 219 bp band, and for the GST T1 were 50-TTC CTT ACT
GGT CCT CAC ATC TC-30 and 50-TCA CCG GAT CAT GGC CAG
CA-30 as forward and reverse primers, respectively, result-
ing in a 450 bp band. As an internal control, the b-globin
gene was amplified using 50-GAA GAG CCA AGG ACA GGT AC-
30and 50 CAA CTT CAT CCA CGT TCA CC 30 as forward and
reverse primers, respectively, giving a 267 bp product. PCR
reactions were resolved in an ethidium bromide-stained 2%
agarose gel electrophoresis. The absence of the GST M1- or
GST T1-specific fragments indicated the corresponding null
genotype (*0/)0), whereas the b-globin-specific fragment
confirmed the presence of amplifiable DNA in the reaction
mixture.
Genotyping for the GST P1 codon 105 (Ile 105 Val) was
determined by PCR-RFLP method in a separate reaction.
The subclasses were amplified using 50-TCA TCC TTC CAC
GCA CAT CC-30 as forward and 50-GCA GGT TGT GTC TTG
TCC CAG-30 as reverse primers, then the 280 bp PCR product
was digested with the restriction enzyme Alw 261(BsmAL)
10 U/50 ml at 37 C for 6 h and analyzed by separation in
a 3% agarose gel and visualized with ethidium bromide. The
homozygous Ile genotype was identified by a 280 bp band,
the homozygous Val genotype was identified by the pres-
ence of 150 and 124 bp bands. The heterozygous type
exhibited all three bands.
PCR reaction mixture contained 2 mM of MgCl2, 0.2 mM
of dNTP, 1 PCR buffer, 1.2 U of Taq DNA polymerase,
100 ng of DNA template and 5 pmol/ml of both forward and
reverse primers in deionized sterile water in total volume
of 50 ml.
Amplification was carried out with touch down method
as follows: 94 C for 30 s (denaturation), 60 C (0.5 C/
cycle, 10 cycle) for 30 s (annealing) and 72 C for 30 s
(extension), then 94 C for 30 s, 55 C for 30 s, and 72 C for
30 s for 35 cycle and 72 C for 10 min as final extension.
Materials
All PCR reagents and ALW26I were purchased from Fer-
mentas, Ukraine. Electrophoreses reagents were from
Invitrogen, USA, other chemicals were obtained from
Merck, Germany.
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Data were analyzed using Chi-square (2 2), three-dimen-
sional contingency table (Chi-square 2 2 2), one-way
and two-way ANOVAs with Tukey post-test and independent
sample t-test accordingly. The p value less than 0.05 was
set as significant. The statistical tests were performed using
SPSS11.5 (SPSS Inc.) and Excel 12.0 (Microsoft Corp.)
softwares.
Results
Over the study time period 30 patients were recruited (15 in
each group) but one from the treatment and two from the
control group were withdrawn (died before completion of
study period). Fourteen of the 27 studied patients received
NAC, and 13 were given placebo. The demographic data are
summarized in Table 1. The groups were well matched in
terms of age, male/female distribution, baseline APACHE II
and PaO2/FiO2, organ dysfunction during ICU stay and
systemic comorbidities.
The genotype frequencies of the GST M1, T1 and P1
polymorphism in both (NAC and control) groups are shown
in Table 2. In control group, the GST M1 gene was deleted in
11 cases (84.6%), and deletion of the GST T1 gene was
identified in 5 cases (38.5%). Deletions of both genes in
a genotype were identified in 5 cases (38.5%) in control
group. In this group of patients, 9 cases (69.2%) were
homozygous for the GST P1 (Ile/Ile), 3 cases (23.1%) were
homozygous for (Val/Val) allele and 1 patient was (7.7%)
heterozygous for the (Ile/Val) alleles.
In the NAC group, deletion of the GST M1 gene was found
in 7 cases (50%), and the GST T1 gene deletion in 7 (50%)
cases. Deletion of both genes was identified in 3 (21%)
cases. In this group of patients, 8 (57.1%) were homozygous
for the GST P1 (Ile/Ile) allele, 5 cases (35.7%) wereTable 2 Genotype frequencies of the GST M1, T1 and P1
polymorphism in both (NAC and control) groups.
NAC group
(nZ 14) n (%)
Control group
(nZ 13) n (%)
P value
GST M1
Null () 7 (50) 11(84.6) 0.066
Present (þ) 7 (50) 2 (15.4)
GST T1
Null () 7 (50) 5 (38.5) 0.547
Present (þ) 7 (50) 8 (61.5)
GST P1
Ile homozygote 8 (57.1) 9 (69.2) 0.77
Val homozygote 5 (35.7) 3 (23.1)
Heterozygote 1 (7.1) 1 (7.7)
GST M1, T1
Null () 3 (21) 5 (38.5) 0.33
P value was calculated using Chi-square tests. The Ile105Val
variant of GST P1 was genotyped in all subjects.homozygous for the GST P1 (Val/Val) allele and 1 (7.1%)
heterozygous for the (Ile/Val) alleles.
The differences in the GST M1, P1 and T1 genotype
distribution between the NAC and the control group were
not statistically significant (p> 0.05). Also insignificant
difference between groups (p> 0.05) in simultaneous
deletions of both genes in a genotype (double null geno-
type) was observed.
Clinical outcome
Clinical outcomes are listed in Table 3. The overall hospital
mortality rate was less in NAC group (35.7%; p< 0.05) but
no statistically significant difference between groups, in
duration of mechanical ventilation or length of ICU stay was
observed (p> 0.05). Baseline oxygenation index (PaO2/
FIO2), was similar in both groups, but improved significantly
(p< 0.05) from day 0 to day 4 in the NAC-treated group.
Correlation test did not demonstrate any association
between intubation period and oxygenation changes in our
study.
In order to assess the potential correlation between
systemic comorbidities or simultaneous organ dysfunction
and hospital mortality, the only major clinical end point
that shows statistically significant difference between NAC
and control group, we used Chi-square tests for intra group
assessment. Systemic comorbidities had no effect on
mortality either in NAC or in control group (p> 0.05),
however, simultaneous organ dysfunction showed a corre-
lation with increased mortality in control group (p< 0.05).
t-test analyses showed no statistically significant differ-
ence, in oxygenation indices between dead and live
patients in different days of our study (p> 0.05). In addi-
tion, to address whether GST M1, T1 and P1 variant allele is
associated with increased mortality, or poor oxygenation,
we performed three-dimensional Chi-square (2 2 2) and
two-way ANOVA with Tukey post-test, respectively. Our
results indicated that the oxygenation had been improved
in NAC-treated group compared to control patients;
however, there was no significant association between GST
polymorphism and oxygenation (Table 4). On the other
hand, a significant association was observed between
increased mortality with GST M1 null and double deletion of
both genes (M1, T1), in control group (p< 0.05).Table 3 Clinical outcomes in NAC and control groups.
NAC group
(nZ 14) n (%)
Control group
(nZ 13) n (%)
P value




24.8 8.5 32.9 9.8 0.539
Length of ICU stay 32.9 7.6 42.1 10.3 0.475
PaO2/FiO2 2nd day 227.3 23.9 155.0 15.5 0.020
PaO2/FiO2 3rd day 344.0 38.3 166.5 119.0 <0.001
PaO2/FiO2 4th day 440.9 47.5 151.2 24.6 <0.001
P values were calculated using Chi-square tests (for hospital
mortality), t-test (for ventilation and ICU stay) and one-way
ANOVA with Tukey post-test (for PaO2/FiO2).
Table 4 GST polymorphisms and oxygenation.
Oxygenation in genotype
NAC Control
Day 2 Day 3 Day4 Day 2 Day 3 Day4
GST M1
Null () 214 18.4 266 28.7 380 60.1*** 147 17.4 161 22.2 152 29.2
Present (þ) 240 45.6 421 59.4* 501 70.3*** 196 6.0 192 19.7 144 20.0
GST T1
Null () 239 45.0 319 56.7 399 66.0** 155 31.4 160 29.4 171 51.2
Present (þ) 215 20.2 368 45.2** 482 69.6*** 154 17.8 170 26.4 138 26.4
GST P1
Ile/Ile 198 17.2 327 41.2* 449 65.4*** 173 18.4 174 24.9 171 33.7
Val/Val 222 26.8 313 63.8 382 71.5** 104 19.5 153 39.2 112 6.2
Ile/Val 485 633 660 144 130 310
GST M1, T1
Null () 203 38.9 245 53.4 346 128.8 155 31.3 160 29.3 171 51.2
P value was calculated using two-way ANOVA with Tukey post-test. The Ile105Val variant of GST P1 was genotyped in all subjects.
* p< 0.05 compared to their corresponding control group.
** p< 0.01 compared to their corresponding control group.
*** p< 0.001 compared to their corresponding control group.
Table 5 GST polymorphisms and mortality.
Death in a genotype c2 P value
NAC Control
GST M1
Null () 3/7* 10/11 15.97 <0.01
Present (þ) 2/7 0/2
GST T1
Null () 2/7 5/5 7.18 >0.10
Present (þ) 3/7 5/8
GST P1




Null () 1/3* 5/5 ND ND
P value was calculated using three-dimensional Chi-square
(2 2 2) for GST polymorphism and mortality. The Ile105Val
variant of GST P1 was genotyped in all subjects.
* p< 0.05 mortality rate compared to control group calcu-
lated by t-test. ND, not determined.
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T1 and double deletion (M1, T1) patients significantly. The
2 2 2 Chi-square analysis indicated a correlation
between GST M1 null polymorphism and increase in
mortality (c2Z 15.97, dfZ 4, p< 0.01). Moreover, there
was a trend toward involvement of GST T1 polymorphism
(c2Z 7.18, dfZ 4, p> 0.10) in mortality rate of ARD
patients. These results indicated the importance of NAC
treatment in ARD patients with GST M1 null and GST M1, T1
double null polymorphisms. These data are summarized in
Table 5.
Discussion
Recent research has proven the inflammatory mediators as
key players in the pathogenesis of ALI/ARDS.33 Oxidative
injury compromising endothelial barrier integrity, have
documented role in the pathogenesis of ALI/ARDS34 and the
oxidative burden has been investigated in these patients.
Ortoloni et al. have found that expired ethane, malon-
dialdehyde (MDA), oxidized and reduced glutathione in the
epithelial lining fluid of ARDS patients correlate with
oxidative changes in lungs.35 In oxidative stress situation,
reduced glutathione (GSH) is one of the main intracellular
low molecular weight thiol that acts as a nucleophilic
scavenger and as an enzyme-catalyzed antioxidant in the
event of electrophilic/oxidative tissue injury.36 As a matter
of fact, it has been suggested that repletion of glutathione
may safely be accomplished with NAC, an extremely safe
agent with a wide toxic therapeutic window in ALI/ARDS
patients, and such treatment may shorten the duration of
lung injury.37 Our earlier study have showed that treatment
with NAC can increase extracellular total antioxidant power
and total thiol molecules and improve intracellular gluta-
thione and the outcomes of patients with ALI/ARDS.38In the present study, we have demonstrated that intra-
venous NAC can improve oxygenation in ALI/ARDS patients,
as evidenced by the significant increase in PaO2/FiO2 from
day 1 to day 4 compared to control group (p< 0.05). This
increase is so much that the median of PaO2/FiO2 was over
the threshold for definition of ALI/ARDS in the third and
fourth day of our study in NAC group. These observations
are in agreement with the findings of an earlier study by
Suter et al. which showed that intravenous NAC could
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ventilatory support in patients presenting with mild to
moderate ARDS.18 Another study by Bernard indicated that
NAC has favorable effects in pulmonary vascular resistance,
static compliance, oxygen delivery and oxygen
consumption.39
However, we observed that compared to control group,
NAC treatment did not significantly decrease the period of
ICU stay and ventilatory support requirements. The corre-
lation analyses indicate no relationship between oxygena-
tion and intubation period in NAC group. This perhaps is
due to other complications, for example decreased level of
consciousness has made the extubation of some of these
patients impossible inspiteofacceptableoxygenation indices.
The results of the present study showed that NAC not
only ameliorated the ALI/ARDS by improving oxygenation
but also decreased mortality rate in ALI/ARDS patients
(P< 0.05), as the most important clinical outcome in our
study. A correlation between simultaneous organ dysfunc-
tion and increased mortality in control group was observed.
Since both groups had comparable organ dysfunction at
baseline, we can conclude that NAC has ameliorated the
negative effects of this parameter on mortality in treat-
ment group. The better survival in NAC group is expected to
be related to better oxygenation in these patients;
however, the statistical analyses do not show such an
association. Thus, one can conclude that these are two
separate conditions, and pathologic pathways interfering
with oxygenation may be different from those contributing
to mortality although further study is needed to make firm
conclusion. In this regard, Domenighetti and Suter showed
that in a group of patients with established ARDS, NAC
neither improved systemic oxygenation nor reduced the
need for ventilatory support.19 These controversies may be
due to different study designs in dosing, time of starting
NAC and study populations.
In the last few years there has been enormous interest in
determining the possible role of different polymorphisms
in association with different pathologic conditions, as
with ARDS. There are some known polymorphisms with
proved diagnostic or prognostic role in these patients. For
example the angiotensin-converting enzyme poly-
morphisms (insertion/deletion) have been reported as
significant prognostic factor for the outcome of patients
with ARDS40 or the variations of the vascular endothelial
growth factor gene may contribute to the prognosis in
patients with ARDS via VEGF production.41 There are
various studies indicating the impact of genetic variability
in glutathione-S-transferase (GST) isoforms M1, T1 and P1,
mainly cancer prognosis, metabolism of xenobiotic
and neurological disorders,42e45 which contribute to indi-
vidual susceptibility differences to oxidative stress.
Furthermore, recently it has been reported that GST
polymorphism contributes to progression from bronchial
hyperresponsiveness to asthma in adults.46 Based on these
observations, we investigated the role of GST poly-
morphism, in our study population, to evaluate individual
response to antioxidant drug NAC, as one of the possible
differences in various studies about NAC in ALI/ARDS. Our
results indicate that there is a significant correlation
between GST M1 null polymorphism and increased
mortality in control group. Moreover, we also observeda similar association with mortality and double deletion of
GST M1 and GST T1 in control group of patients. Further-
more, our results indicated that in ARD patients with GST
M1 null and M1, T1 double deletion, NAC treatment
significantly lowers the mortality rate. Although there is
a trend toward involvement of GST T1 polymorphism in
mortality rate of ARD patients, no statistically significant
association between the single GST T1 null/present or GST
P1 polymorphisms and mortality was observed. It is note-
worthy to mention that there are no significant differences
in baseline distribution of three classes of GST enzymes
(GST M1, GST T1 and GST P1) between NAC and control
group. These results suggest that patients with absence of
GST M1 gene or deletion of both GST M1 and GST T1, are
more vulnerable to oxidative stress contributing to ALI/
ARDS and are in immediate need of antioxidant therapy. It
should be mentioned that in patients with GST T1 null and
GST P1 Val/Val homozygote polymorphism, an increase in
mortality rate in control group has been observed although
it is not statistically significant which is perhaps because of
the small number of patient in these groups. On the other
hand, GST polymorphisms showed no association with the
fluctuation in oxygen indices in both NAC and control
groups, although there was better oxygenation in some
polymorphisms. As the GST polymorphisms, one of the
oxidative stress related enzymes, was more prominent in
altering mortality compare to oxygenation, we can assume
that confronting with oxidative stress is an important
mechanism contributing to mortality. Perhaps other
mechanisms in addition to antioxidant effects of NAC, are
contributing to improve oxygenation in patients. Further-
more, the role of GST polymorphisms in pathogenesis and
prognosis of different lung diseases have been inves-
tigated.23e26 The GST P1 is the major isoform in the human
lung, with the common polymorphism leading to replace-
ment of the amino acid Val with Ile at codon 105. This
substitution results in three possible genotypes: 105 Ile/
Ile, 105 Ile/Val, or 105 Val/Val, and also changes the
enzyme’s active site and its substrate-specific catalytic
activity.21,23 These polymorphisms have been studied
widely as a potential contributor in asthma, COPD and lung
cancers, however, the data are still conflicting.25e27 Our
result indicated a significant increase in oxygenation in
NAC-treated patients compared to control; however, no
significant association between GST polymorphism and
oxygenation was observed.
Based on these observations, one can assume that
discrepancies in clinical studies can be explained by genetic
variations in GST isoforms of studied population. As
a result, our study indicates the importance of GST geno-
typing in predicting patient’s clinical response to NAC
treatment.
In conclusion our results indicate that treatment with
NAC has a beneficial effect in ALI/ARDS patients by
improving oxygenation and decreasing mortality rate.
Furthermore, the genotyping of GST M1, P1 and T1 classes
will have further impact on outcome of treatment, since
NAC is required in patients with GST M1 null or GST M1 and
T1 double null genotypes. Although this study proved major
benefit of NAC treatment in ALI/ARDS and requirement of
GST genotyping, further studies with larger patient sample
size will provide better treatment protocols.
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